Cargando…

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease

Background: It is reported that various diseases such as non-alcoholic fatty liver disease (NAFLD) are associated with imbalance of microbiome. And FXR has been well investigated in liver diseases. Purpose: The objective of this study was to identify the role of farnesoid X receptor agonist obeticho...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Dan-Ying, Zhu, Lin, Liu, Hai-Ning, Tseng, Yu-Jen, Weng, Shu-Qiang, Liu, Tao-Tao, Dong, Ling, Shen, Xi-Zhong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617567/ https://www.ncbi.nlm.nih.gov/pubmed/31308634 http://dx.doi.org/10.2147/DDDT.S207277

Ejemplares similares

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid
por: de Haan, Lianne R., et al.
Publicado: (2021)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
por: van Golen, Rowan F., et al.
Publicado: (2018)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway
por: Attia, Yasmeen M., et al.
Publicado: (2017)

Comparative potency of obeticholic acid and natural bile acids on FXR in hepatic and intestinal in vitro cell models
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

Berberine Alleviates Non-alcoholic Steatohepatitis Through Modulating Gut Microbiota Mediated Intestinal FXR Activation
por: Shu, Xiangbing, et al.
Publicado: (2021)

Discovery biomarker to optimize obeticholic acid treatment for non-alcoholic fatty liver disease
por: Lee, Seung Min, et al.
Publicado: (2023)

Activation of FXR by obeticholic acid induces hepatic gene expression of SR-BI through a novel mechanism of transcriptional synergy with the nuclear receptor LXR
por: Dong, Bin, et al.
Publicado: (2019)

Alcoholic liver steatosis in mice is aggravated by low-protein diet and reversed by FXR agonist
por: Lívero, Francislaine Aparecida dos Reis, et al.
Publicado: (2012)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Fatty liver diseases, bile acids, and FXR
por: Zhu, Yan, et al.
Publicado: (2016)

Obeticholic Acid Inhibits Anxiety via Alleviating Gut Microbiota-Mediated Microglia Accumulation in the Brain of High-Fat High-Sugar Diet Mice
por: Wu, Li, et al.
Publicado: (2021)

Diammonium Glycyrrhizinate Ameliorates Obesity Through Modulation of Gut Microbiota-Conjugated BAs-FXR Signaling
por: Li, Yun, et al.
Publicado: (2021)

Comparing the Efficacy and Safety of Obeticholic Acid and Semaglutide in Patients With Non-Alcoholic Fatty Liver Disease: A Systematic Review
por: Ahmed, Nabeel R, et al.
Publicado: (2022)

Effect of FXR agonist GW4064 in the treatment of hilar cholangiocarcinoma in rats
por: Wang, Jie-ping, et al.
Publicado: (2022)

Liver Capsule: FXR agonists against liver disease
por: Fuchs, Claudia D., et al.
Publicado: (2016)

Non-alcoholic fatty liver and the gut microbiota
por: Bashiardes, Stavros, et al.
Publicado: (2016)

Obeticholic Acid: A New Era in the Treatment of Nonalcoholic Fatty Liver Disease
por: Abenavoli, Ludovico, et al.
Publicado: (2018)

Akkermansia muciniphila and Bifidobacterium bifidum Prevent NAFLD by Regulating FXR Expression and Gut Microbiota
por: Nian, Fulin, et al.
Publicado: (2023)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

SUMOylation inhibitors synergize with FXR agonists in combating liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2020)

Natural Product 2-Oxokolavenol Is a Novel FXR Agonist
por: Guo, Fusheng, et al.
Publicado: (2022)

Naturally Occurring TPE-CA Maintains Gut Microbiota and Bile Acids Homeostasis via FXR Signaling Modulation of the Liver–Gut Axis
por: Liu, Linlin, et al.
Publicado: (2020)

Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
por: Sharma, Satya Priya, et al.
Publicado: (2021)

Depletion of gut microbiota induces skeletal muscle atrophy by FXR-FGF15/19 signalling
por: Qiu, Yixuan, et al.
Publicado: (2021)

Alterations in the gut microbiota and serum metabolomics of spontaneous cholestasis caused by loss of FXR signal in mice
por: Wei, Shizhang, et al.
Publicado: (2023)

Astaxanthin Prevents Alcoholic Fatty Liver Disease by Modulating Mouse Gut Microbiota
por: Liu, Huilin, et al.
Publicado: (2018)

FXR and TGR5 Agonists Ameliorate Liver Injury, Steatosis, and Inflammation After Binge or Prolonged Alcohol Feeding in Mice
por: Iracheta‐Vellve, Arvin, et al.
Publicado: (2018)

Probiotics Alleviated Nonalcoholic Fatty Liver Disease in High-Fat Diet-Fed Rats via Gut Microbiota/FXR/FGF15 Signaling Pathway
por: Luo, Minmin, et al.
Publicado: (2021)

Non-alcoholic fatty liver disease, diet and gut microbiota
por: Finelli, Carmine, et al.
Publicado: (2014)

Effects of cholesterol-lowering probiotics on non-alcoholic fatty liver disease in FXR gene knockout mice
por: Yang, Minghua, et al.
Publicado: (2023)

FXR Controls the Tumor Suppressor NDRG2 and FXR Agonists Reduce Liver Tumor Growth and Metastasis in an Orthotopic Mouse Xenograft Model
por: Deuschle, Ulrich, et al.
Publicado: (2012)

Caenorhabditis Intervention Testing Program: the farnesoid X receptor agonist obeticholic acid does not robustly extend lifespan in nematodes
por: Morshead, Mackenzie L, et al.
Publicado: (2020)

Bioenergetic cues shift FXR splicing towards FXRα2 to modulate hepatic lipolysis and fatty acid metabolism
por: Correia, Jorge C., et al.
Publicado: (2015)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
por: Liu, Szu-Yu, et al.
Publicado: (2022)

Dysbiosis of gut microbiota after cholecystectomy is associated with non‐alcoholic fatty liver disease in mice
por: Wang, Qihan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1ei08l6l8g7etk8nebk5j9egqb